A deal between Pfizer and former President Donald Trump is sending shockwaves through both the healthcare industry and Washington — and not everyone saw it coming.
Pfizer, one of the largest pharmaceutical companies in the world, has agreed to cut the price of its prescription drugs for the Medicaid program — slashing costs to match what’s charged in other developed nations. In return? Tariff relief from the Trump administration.
That’s not a typo. This is a “most-favored-nation” deal. And for a system long accused of charging Americans two, even three times more than patients overseas… this announcement signals a massive shift.
But there’s a catch — and it’s a big one.
The price cuts only apply to Medicaid, not Medicare. That means seniors, many of whom take multiple medications, won’t see any of the discounts in this deal. Not yet, at least.
And while 70 million Americans rely on Medicaid, it’s Medicare that swallows the lion’s share of drug spending. In 2021, Medicare shelled out over $216 billion on medications. Medicaid? Roughly $80 billion.
Still, Trump made it clear: this is just the beginning.
In a press conference that caught several other drug companies off guard, Trump, standing beside Pfizer CEO Albert Bourla and Health Secretary Robert F. Kennedy Jr., declared the U.S. is “done subsidizing the healthcare of the rest of the world.” He announced that TrumpRx — a direct-to-consumer drug pricing website — will launch in 2026.
BREAKING: President Trump just announced he’s struck a deal with Pfizer to offer MASSIVE discounts on their drugs, follow his demands to lower prices for Americans
A new government website, TrumpRx, will also be available for consumers to DIRECTLY purchase drugs, cutting out… pic.twitter.com/kUbiNeXGXo
— Nick Sortor (@nicksortor) September 30, 2025
BREAKING: President Trump just announced he’s struck a deal with Pfizer to offer MASSIVE discounts on their drugs, follow his demands to lower prices for AmericansThe crowd behind this announcement wasn’t just political. It was strategic.
The moment the news dropped, Pfizer’s stock jumped more than 6%. Other major drugmakers — including Eli Lilly, Merck, and GSK — saw gains too. Why? Because investors realized the fine print: the price cuts aren’t industry-wide. They’re limited. And they come with a tradeoff — no tariffs for Pfizer for at least three years.
That’s provided they move manufacturing to the U.S.
Pfizer has nine facilities in the United States and 28 overseas, including in countries like Ireland and Japan. Under this deal, the company will pour $70 billion into U.S. manufacturing and R&D. That investment bought them a pause on the looming 100% tariffs Trump threatened for branded drugs imported into the U.S., set to begin October 1.
This wasn’t a quiet negotiation behind closed doors. Trump sent letters to 17 top drugmakers back in July, giving them until September 29 to cut prices or face consequences. Pfizer was the first to act — and may have set a precedent.
RFK Jr. heaps praise on President Trump for 2 minutes straight after he struck a deal that other politicians said was impossible.
Trump forced Pfizer and other pharmaceutical giants to sell their prescription drugs to Medicaid at the “most favored nation’s prices” — the same… pic.twitter.com/88csLcZBot
— Vigilant Fox
(@VigilantFox) Now the pressure’s on.
Several other pharmaceutical giants, including AstraZeneca and Eli Lilly, have made quiet moves toward increasing domestic production. But this was the first real shot fired. And it came with some real numbers: up to 85% savings on drugs like Xeljanz, Zavzpret, Eucrisa, and Duavee — medications that can cost thousands per month.
It sounds like a win — but only if you’re on Medicaid.
The rest of America’s patients? They’re watching from the sidelines.
And not all are happy with this deal:
Pfizer released an unsafe and ineffective product onto the market which was then mandated by the federal government. Countless people died. Instead of facing justice, Trump just handed them 70 billion dollars to further grow his mRNA death jab empire.pic.twitter.com/6hKZ8wq1AF
— Clint Russell (@LibertyLockPod) September 30, 2025
Trump just praised his “friend” Pfizer CEO Albert Bourla who lied about vaccine efficacy and responsible for the deaths of 470,000 people
Infuriating! I feel so betrayed
— It’s
Tiff Critics, economists, and investors alike are wondering: Will other companies follow Pfizer’s lead? Or will they dig in and gamble on surviving the tariffs?
Pfizer’s move also raises deeper questions. If these drugs can suddenly cost 50–85% less under a new agreement… why have Americans been paying the higher price all along?
And why is it only now — under threat of tariffs — that change is happening?
Industry insiders suggest the damage to pharma companies may not be as bad as it sounds. Medicaid already receives deep discounts. According to Gabelli Funds’ Daniel Barasa, many rebates already exceed 80%, so this deal might not sting quite as much as it looks on paper.
Still, for everyday Americans watching drug prices climb year after year, the symbolism is huge.
Pfizer blinked. Trump pushed. And now there’s a crack in the wall of pharmaceutical pricing — one that could grow fast.
However, as it stands, the largest healthcare program in America — Medicare — remains untouched.
And the millions of families crushed under the weight of out-of-pocket prescription costs?
They’re still waiting.
